Due to 'overwhelming demand,' Sanofi and AstraZeneca's RSV antibody to be in limited supply - Endpoints News
endpts.comSubmitted by endpointsnews6292 in health
Sanofi is expecting supply constraints of its infant RSV antibody Beyfortus, which it co-developed with AstraZeneca, in the first quarter of this year. While it is expecting to boost production, the company says it’s too early to say by how much. The French p…